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ABSTRACT
TAZ, a transcriptional coactivatorwith PDZ-bindingmotif,
is encoded by WWTR1 gene (WW domain containing
transcription regulator 1). TAZ is tightly regulated in the
hippo pathway-dependent and -independent manner in
response to a wide range of extracellular and intrinsic
signals, includingcell density, cell polarity, F-actin related
mechanical stress, ligands of G protein-coupled recep-
tors (GPCRs), cellular energy status, hypoxia and osmo-
tic stress. Besides its role in normal tissue development,
TAZplayscritical roles incell proliferation, differentiation,
apoptosis, migration, invasion, epithelial-mesenchymal
transition (EMT), and stemness in multiple human can-
cers. We discuss here the regulators and regulation of
TAZ. We also highlight the tumorigenic roles of TAZ and
its potential therapeutic impact in human cancers.
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INTRODUCTION
TAZ (Transcriptional coactivator with PDZ-binding motif), also
known as WW domain containing transcription regulator 1
(WWTR1), was ﬁrstly identiﬁed as a 14-3-3 binding phos-
phoprotein (Kanai et al., 2000). TAZ is not a transcription
factor because of lacking a DNA-binding domain, while TAZ
could serve as a transcriptional regulator via its intrinsic
transactivation domain (Kanai et al., 2000). TAZ has been
implicated to interact with multiple transcription factors
including RUNX2 (runt-related transcription factor 2) (Cui
et al., 2003; Hong et al., 2005), MyoD (myoblast determina-
tion protein 1) (Jeong et al., 2010), PPAR (peroxisome pro-
liferator-activated receptor) (Hong et al., 2005), TTF1 (thyroid
transcription factor 1) (Di Palma et al., 2009; Park et al.,
2004), PAX3 (paired box gene 3) (Murakami et al., 2006),
PAX8 (paired box gene 8) (Di Palma et al., 2009), Smads
(Varelas et al., 2008; Varelas et al., 2010), and TEADs (TEA
domain transcription factors) (Mahoney et al., 2005; Zhang
et al., 2009). Collaborating with these transcription factors,
TAZ plays important roles during osteoblastic, myogenic,
adipogenic differentiation (Hong & Yaffe, 2006). Although
TAZ mainly functions as a transcriptional coactivator, recent
studies have also elucidated that TAZ serves as a tran-
scriptional repressor (Kim et al., 2015; Valencia-Sama et al.,
2015). Since TAZ was ﬁrstly identiﬁed as a 14-3-3 binding
protein, the mechanism for the speciﬁc regulation of TAZ was
uncovered until 2008. Lei et al. demonstrated that TAZ is
tightly regulated by the Hippo signaling pathway. Phospho-
rylation of TAZ at serine 89 is required for its interaction with
14-3-3 and substantial sequestration in the cytoplasm (Lei
et al., 2008). Besides the 14-3-3 binding motif, WW domain,
coiled-coil domain, and PDZ-binding motif within TAZ have
important functions for the interaction with other partners of
TAZ as well (Chan et al., 2011; Remue et al., 2010). TAZ-
deﬁcient mice develop signiﬁcant renal cyst as early as
embryonic day 15.5. Three weeks after birth, only one-ﬁfth of
TAZ-deﬁcient mice are alive with dilated calyces, multiple
renal cysts, and lung emphysema (Hossain et al., 2007;
Makita et al., 2008; Tian et al., 2007). Till now, the in vivo
pathogenic mechanism of TAZ has not been fully uncovered
(Tian et al., 2007). Accumulating studies indicated that TAZ is
an oncogenic protein during tumorigenesis via promoting cell
proliferation, migration, and EMT (Chan et al., 2008; Chan
et al., 2009; Lei et al., 2008; Zhang et al., 2009). Consistently,
the expression of TAZ is elevated in multiple human cancers,
such as invasive ductal breast cancer and glioblastoma (Bhat
et al., 2011; Chan et al., 2008; Cordenonsi et al., 2011; Zhou
et al., 2015a), implying the oncogenic roles of TAZ in human
cancer development. Here we summarize the current
understanding of the biochemical regulation of TAZ, highlight
the intrinsic and extracellular signals that modulating TAZ
activity, and emphasize the relevance of TAZ and human
cancers.
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REGULATORY MECHANISMS FOR TAZ
As a transcriptional coactivator, TAZ is tightly regulated at
certain layers. TAZ could be directly phosphorylated by
LATS1/2 (the Hippo signaling), Cdk1, GSK3 or c-Abl in dif-
ferent circumstances; subcellular localization of TAZ is con-
trolled by the Hippo signaling pathway in response to a
bench of signals; LATS1/2, CK1, and GSK3 contribute to the
protein stability regulation of TAZ; a negative feedback loop
exists between TAZ and YAP; and the expression of TAZ is
modulated by different miRNAs in cancer cells. Disturbance
of any of these regulations may contribute to the oncogenic
roles of TAZ in human cancer.
Direct phosphorylation of TAZ
The Hippo pathway
The Hippo pathway plays a crucial role in organ size control
and is highly conserved from Drosophila to mammals. TAZ
and YAP (yes-associated protein), two mammalian homolo-
gous to Drosophila Yorkie, serve as two core downstream
effectors of the Hippo signaling pathway which comprises an
upstream kinase cascade and a downstream transcription
module (Fig. 1). In a classical view, MST1/2, in complex with
the non-catalytic partner SAV1, phosphorylate and activate
LATS1/2, the NDR-family kinases. LATS1/2 are fully acti-
vated by MOB1 and then phosphorylate the downstream
targets, i.e., YAP and TAZ (Bothos et al., 2005; Chan et al.,
2005; Harvey & Tapon, 2007; Hergovich, 2011; Hergovich
et al., 2006; Hoa et al., 2016; Zhao et al., 2010a). Although
LATS1/2 are the kinases of TAZ, the requirement of MST1/2
for the phosphorylation and activation of LATS1/2 is cell
type- and context-dependent. Recently, another pathway
activating LATS1/2 was identiﬁed (Li et al., 2014; Meng et al.,
2015; Zheng et al., 2015). Three groups independently found
that MAP4K family members—Drosophila Happyhour
(Hppy) homologues MAP4K1/2/3 and Misshapen homo-
logues MAP4K4/6/7—serve as evolutionarily conserved
direct kinases of LATS1/2 (Li et al., 2014; Meng et al., 2015;
Zheng et al., 2015). Deletion of both MST1/2 and MAP4Ks
but neither alone abolishes the phosphorylation of LATS1/2
(and thereby phosphorylation and inactivation of YAP/TAZ)
in response to a wide range of upstream signals. Taken
together, MST1/2 and MAP4Ks are two major kinase fami-
lies, which can phosphorylate LATS1/2 directly upon multiple
signals, to modulate the activity of TAZ. Elucidating the
context dependency of MAP4Ks and MST1/2 will shed light
on the regulation of TAZ.
When serine 89 of TAZ is phosphorylated by LATS1/2,
TAZ is sequestrated in the cytoplasm by 14-3-3 to inhibit its
nuclear functions (Lei et al., 2008). Multiple intrinsic and
extracellular signals can inhibit the signaling cascade of the
Hippo pathway, leading to the dephosphorylation and
nuclear localization of TAZ (Liu et al., 2011; Yu et al., 2015).
TEAD family transcription factors are the major binding
partner of TAZ in the nucleus. The dephosphorylated TAZ
interacts with TEADs and serves as a transcriptional coac-
tivator to regulate the expression of a set of genes regarding
cell proliferation, migration, and apoptosis (Zhang et al.,
2009). It’s not clear whether the interaction between TAZ and
other transcription factors would be regulated by the Hippo
pathway.
Numerous in vitro studies identiﬁed that TAZ serves as an
oncoprotein in cancer cells by supporting cell proliferation,
migration, and EMT (Chan et al., 2008; Lei et al., 2008).
While a rare mutation of WWTR1, which encodes TAZ pro-
tein, was observed in human cancer specimens (Gao et al.,
2013). Interestingly, the expression level of TAZ protein was
elevated in high-grade metastatic breast cancers (Chan
et al., 2008; Cordenonsi et al., 2011). Several studies on the
regulation of TAZ stability provided the explanation, at least
partially, for the elevated TAZ level in human cancers.
It was believed the major regulatory mechanism of the
Hippo pathway on TAZ is via modulating TAZ translocaliza-
tion between cytoplasm and nucleus (Lei et al., 2008). Until
2010, Liu et al. uncovered that TAZ is a very unstable protein
and degraded in cells under high cell density, and the sta-
bility of TAZ is regulated by the Hippo pathway, too (Liu et al.,
2010). In response to high cell density, the Hippo pathway is
highly activated and TAZ is primarily phosphorylated at
serine 311 by LATS1/2 and further phosphorylated by CK1 at
serine 314. The phosphorylated TAZ creates a phosphode-
gron for the recognition by the F-box protein β-TrCP. As a
component of E3 ligase complex, β-TrCP recruits TAZ to the
SCF/CRL1(β-TrCP) E3 ligase to carry on the polyubiquity-
lation and degradation (Liu et al., 2010). These studies
suggest that TAZ could be regulated by the Hippo pathway
via two distinct mechanisms, i.e. localization and stability
(Fig. 1).
The AKT/GSK3 pathway
During cell contact inhibition, the Hippo pathway will be
activated and then phosphorylated TAZ at serine 311 for
further degradation by SCF/CRL1(β-TrCP) E3 ligase (Liu
et al., 2010). Compared with YAP, TAZ has two phospho-
degrons which can be recognized by β-TrCP (Huang et al.,
2012; Liu et al., 2010; Zhao et al., 2010b). Besides the
C-terminal phosphorylation of TAZ by LAT1/2, Huang and
colleagues showed that the N-terminal of TAZ is phospho-
rylated by GSK3β at serine 58 and serine 62 directly. The
phosphorylated serine 58 and serine 62 on TAZ create an
N-terminal phosphodegron for β-TrCP recognition, interac-
tion and further polyubiquitylation and degradation of TAZ
(Huang et al., 2012). They further provided evidence that the
N-terminal phosphorylation of TAZ is regulated by the PTEN/
PI3K/AKT pathway but independent of the Hippo signaling
pathway. Moreover, they observed that the protein level of
TAZ correlates with the PI3K signaling activity, i.e., TAZ is
elevated in PTEN mutant cancer cells (Huang et al., 2012).
As we know, the PI3K/AKT pathway is frequently altered in
multiple cancer types (Luo et al., 2003; Yuan & Cantley,
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2008). This novel mechanism for TAZ stability regulation
indicates that TAZ might be a crucial oncoprotein which acts
downstream of the PI3K/AKT pathway during tumorigenesis.
Taken together, the N-terminal and C-terminal phosphode-
grons of TAZ which are responsible for the stability regula-
tion of TAZ are differently modulated by the PI3K/AKT and
the Hippo signaling pathways, suggesting that the protein
level of TAZ can be manipulated in response to a wide range
of intrinsic and extracellular signals through these two
pathways. Recently, Feng et al. found that there is increased
protein level and nuclear accumulation of TAZ during LPL1-
induced osteogenic differentiation (Feng et al., 2015). Inter-
estingly, this phenomenon relies on the AKT/GSK3β path-
way but not LATS1/2 to stabilize TAZ. It’s well known that
TAZ plays an important role during mesenchymal stem cell
differentiation (Hong & Yaffe, 2006). However, how TAZ is
regulated during differentiation remains unclear. Further
studies will uncover the regulation of the Hippo pathway and
the AKT/GSK3β pathway on TAZ during differentiation
stages. Elucidating the contribution and collaboration of
these two distinct pathways on TAZ regulation will provide
novel insight into the elevated TAZ level in human cancer.
Cdk1
Besides LATS1/2 and GSK3, a new layer of phosphorylation
regulation on TAZ has been identiﬁed recently from two
independent groups (Zhang et al., 2015b; Zhao & Yang,
2015). Zhang and colleagues showed that the phosphory-
lation status of TAZ is changed during antimitotic drug-in-
duced G2/M arrest. In vitro and in vivo studies demonstrated
that TAZ is phosphorylated by the mitotic kinase cyclin-de-
pendent kinase 1 (Cdk1) at serine 90, serine 105, threonine
326, and threonine 346 during the G2/M phase of the cell
cycle. The mitotically phosphorylated TAZ is more oncogenic
with stronger transcriptional activity. What’s more, if these
sites cannot be properly phosphorylated by Cdk1, mitotic
defects can be induced in MCF10A cells (Zhang et al.,
2015b). Similarly, Zhao et al. observed that Taxol-induced
TAZ phosphorylation and degradation is not dependent on




































Figure 1. The core of the Hippo signaling pathway. The core components of the Hippo pathway comprise a kinase cascade and a
transcriptional activation module. When the Hippo pathway is activated, mammalian STE20-like 1/2 (MST1/2) phosphorylate and
form complex with Salvador 1 (SAV1). MST1/2 phosphorylate and activate large tumor suppressor 1/2 (LATS1/2) and Mob1 homolog
(MOB1). Beside MST1/2, MAP4K family members could directly phosphorylate LATS1/2 as well. Two homologues transcriptional
coactivator yes-associated protein (YAP) and WW domain-containing transcription factor (TAZ) are phosphorylated and inactivated
by LATS1/2 via cytoplasmic retardation by 14-3-3 or degradation by SCF/CRL1(β-TrCP) E3 ligase. When the Hippo pathway is
inactivated, MST1/2 and LATS1/2 are dephosphorylated and inactivated, resulting in the dephosphorylation and nuclear localization
of YAP/TAZ. As transcriptional coactivators, the nuclear YAP/TAZ bind to and activate TEA domain family members 1–4 (TEAD1–4),
leading to the transcription of genes relating to cell proliferation, migration, and tumorigenesis.
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showed that Cdk1 directly phosphorylates TAZ on six novel
sites (serine 90, serine 105, threonine 175, threonine 285,
threonine 326, and threonine 346). The phosphorylated TAZ
is quite unstable in response to Taxol treatment, leading to
the abolishment of TAZ-induced anti-tubulin drug resistance.
In contrast, the dephosphorylation-mimicking mutant of TAZ
is resistant to both Taxol and Vinblastine (Zhao & Yang,
2015). This study not only provides a novel kinase of TAZ, it
also suggests that Cdk1-TAZ signaling plays a crucial role in
anti-tubulin drug resistance in cancer cells. As we can
compare, the phosphorylation sites from these two studies
are almost the same, however, most of these sites are not
conserved from YAP (Bui et al., 2016; Yang et al., 2013).
YAP and TAZ share the similar regulatory mechanism under
the modulation of the Hippo signaling pathway. It’s very
interesting to identify the different regulatory mechanism of
TAZ by other kinases, such as Cdk1.
As we know, SCF/CRL1(β-TrCP) is the bona ﬁde E3
ligase for TAZ degradation. However, disruption of both
phosphodegrons for β-TrCP recognition on TAZ doesn’t
signiﬁcantly rescue Taxol-induced TAZ degradation, and the
interaction between TAZ and β-TRCP is independent of
Cdk1 phosphorylation. These data strongly imply that the E3
ligase which is responsible for TAZ degradation upon Taxol
treatment may not be β-TRCP. It’s intriguing to identify the
novel E3 ligase which is responsible for Taxol-induced TAZ
degradation by screening a pool of E3 ligase siRNA library.
c-Abl
In contrast to the phosphorylation of TAZ on serine or thre-
onine, tyrosine phosphorylation also exists on TAZ. A recent
study showed that TAZ undergoes tyrosine phosphorylation
at tyrosine 316 by c-Abl kinase under hyperosmotic stress.
The tyrosine phosphorylated TAZ selectively binds to
nuclear factor of activated T cells 5 (NFAT5) and thereby
inhibits its DNA-binding and transcriptional activity (Jang
et al., 2012). This ﬁnding not only raised a novel type of
phosphorylation on TAZ but also provided an intriguing
hypothesis that TAZ can function as a transcriptional co-
repressor of NFAT5 in renal cells under hypertonic condition.
The TAZ-NFAT5 axis may provide a potential explanation for
the TAZ deﬁciency-induced multiple kidney cysts (Hossain
et al., 2007; Makita et al., 2008). The physiological signiﬁ-
cance of this phenomenon remains to be explored by future
work.
Feedback regulation from YAP
Intrinsic negative feedback loop is a broadly observed phe-
nomenon in cells and plays important roles in maintaining
homeostasis. This is true for YAP/TAZ feedback regulation.
Moroishi et al. showed that elevated expression of YAP
leads to the decrease of TAZ protein level in both cultured
cells and mouse tissues. This phenomenon is dependent on
TEADs-induced transcription of LATS1/2 and NF2
(neuroﬁbromin 2), leading to the increase of both protein
level and activity of LATS1/2 and thereby inhibition and
degradation of TAZ (Moroishi et al., 2015). Interestingly, the
stability of YAP is also regulated by TAZ in a similar negative
feedback loop manner (Moroishi et al., 2015). This smart
negative feedback loop establishes an efﬁcient way to
maintain the homeostasis of YAP/TAZ levels within cells.
Similarly, Finch-Edmondson and colleagues found that TAZ
protein accumulation is negatively regulated by YAP abun-
dance in multiple mammalian cells (Finch-Edmondson et al.,
2015). Both studies showed that this negative feedback loop
is dependent on TEADs and LATS1/2. However, there are 2
major differences between Finch-Edmondson’s and Mor-
oishi’s work: 1) Finch-Edmondson’s data showed that this
negative feedback loop is uni-directional, i.e. only YAP
expression level regulates TAZ degradation, but not in a
reverse way; 2) Moroishi’s data support this feedback loop
totally relies on LATS1/2, suggesting that YAP-induced TAZ
reduction acts through LATS1/2 mediated degradation of
TAZ via its C-terminal phosphodegron; while Finch-Ed-
mondson implied that GSK3 but not CK1 is required for YAP-
induced TAZ degradation, supporting that the N-terminal
phosphodegron of TAZ may contribute to this speciﬁc mod-
ulation. These two studies identiﬁed novel regulatory
mechanisms that maintaining YAP/TAZ at a constant level.
Disruption of this homeostasis may be involved in
tumorigenesis.
Regulation of TAZ by microRNA
As we know from the well-established Hippo signaling
pathway, the activity of TAZ is tightly regulated by phos-
phorylation from LATS1/2 (Yu et al., 2015; Zhao et al., 2008).
However, more and more studies from clinic specimens
imply that the mRNA level of TAZ is upregulated in these
cancer samples, at least partially, because of the modulation
from miRNAs. Yuan et al. found that miR-125a-5p is rever-
sely correlated with TAZ in multiple glioma cell lines by tar-
geting 3′UTR of TAZ mRNA directly and promoting its
degradation. Furthermore, miR-125a-5p-induced cell growth
inhibition and differentiation could be rescued by TAZ over-
expression (Yuan et al., 2015). Recently, Li et al. reported
that miR-125b directly targets TAZ by binding to its 3′UTR.
Moreover, overexpression of TAZ impairs the miR-125b-in-
duced inhibitory effect on growth and invasion of HCC cells
(Li et al., 2015a). Based on a cancer-related miRNA
screening in HCC cell lines, Higashi and colleagues showed
that the mRNA level of miR-9-3p is inversely correlated with
TAZ in HCC patients. However, whether TAZ serves as a
major downstream target of miR-9-3p which inhibits HCC
cell proliferation remains elusive (Higashi et al., 2015). Zuo
and colleagues demonstrated that TAZ is one of the direct
targets of miR-141 which was signiﬁcantly decreased in
gastric cancer. The growth inhibitory effect of miR-141 in
gastric cancer cells dependents on TAZ (Zuo et al., 2015). In
ovarian cancer cells, TAZ is validated as a direct target of
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miR-129-5p which plays a tumor-suppressive role in ovarian
cancer. The inverse correlation between TAZ and miR-129-
5p in ovarian cancer samples indicates that this regulation
exists in vivo as well (Tan et al., 2015). Besides these
miRNAs which directly bind to the mRNA of TAZ, other
miRNAs which can modulate the upstream components of
the Hippo signaling pathway are also involved in the acti-
vation of TAZ. For example, miR-130b directly represses
MST1 and SAV1 expression in human glioblastoma cells
and hence activates TAZ and TEAD transcription activity
(Zhu et al., 2015). Interestingly, a recent study by Mori and
colleagues uncovered that YAP/TAZ regulates cell-density-
dependent global miRNA biogenesis by modulating the
microprocessor machinery (Mori et al., 2014), implying a
novel mechanism of YAP/TAZ in controlling cell growth and
cancer. Taken together, YAP/TAZ are regulated by miRNAs
and can regulate miRNA processing, leading us to consider
whether a feedback loop exists between YAP/TAZ and
miRNAs. Actually, Shen et al. provided an example for the
feedback loop. One of the direct YAP targets, miR-130a,
could strongly repress the inhibitory effect of VGLL4 on YAP,
leading to the constitutive activation of YAP (Shen et al.,
2015). The feedback loop between miRNA and YAP/TAZ
might be involved in tissue homeostasis and cancer
development.
INTRINSIC AND EXTRACELLULAR SIGNALS
MODULATING TAZ
Extensive studies have identiﬁed numerous intrinsic and
extracellular signals stimulating the Hippo signaling pathway,
including contact inhibition, mechanic stress, cell junction,
cytoskeletal rearrangement, cellular energy status, and the
ligands stimulating GPCRs (Hansen et al., 2015; Yu et al.,
2015) (Fig. 2). Other signals, such as hypoxia and osmotic
stress, could modulate TAZ in a way independent of the
Hippo signaling pathway (Hansen et al., 2015; Yu et al.,
2015). The various stimuli on TAZ make it quite dynamic.
How these signals are integrated to regulate TAZ under
complex circumstances is very intriguing.
Actin cytoskeleton integrates signals
Basically, the actin cytoskeleton and Rho-ROCK are impor-
tant for maintaining the cell morphology and regulating cell
proliferation and differentiation (Jaffe and Hall, 2005).
Recent studies demonstrated that Rho GTPase and the
dynamic of actin cytoskeleton play a central role in the reg-
ulation of the Hippo-YAP/TAZ signaling pathway (Fig. 2). 1)
Multiple ligands of GPCRs could active/inactive TAZ via
regulating Rho GTPase and actin cytoskeleton arrangement
(Miller et al., 2012; Mo et al., 2012; Yu et al., 2012; Zhou
et al., 2015a); 2) Overexpression of a constitutively active
form of Rho GTPase or inhibition of Rho GTPase by C3 toxin
strongly modulates the activity of TAZ (Dupont et al., 2011;
Yu et al., 2012; Zhao et al., 2012). 3) Cell detachment
inactivates TAZ via regulating cytoskeleton organization
(Zhao et al., 2012); 4) Mechanical cues exerted by extra-
cellular matrix stiffness and cell shape modulate TAZ activity,
and this phenomenon requires Rho GTPase (Dupont et al.,
2011); 5) Contact inhibition which will change the F-actin
arrangement leads to the inactivation of TAZ (Lei et al., 2008;
Liu et al., 2010). Actin cytoskeleton appears to be the master
regulator of the Hippo-YAP/TAZ pathway, and multiple
extracellular signals are integrated to the cytoskeleton reor-
ganization to transduce the signals to the core of the Hippo
kinases module. However, how the cytoskeleton arrange-
ment is sensed by the Hippo pathway remains elusive.
Another interesting observation is that the F-actin arrange-
ment is tightly regulated by TAZ during EMT processes (Lei
et al., 2008; Liu et al., 2010). For the extensive discussion
and implication of actin cytoskeleton and the Hippo signaling
pathway, please refer to other insightful reviews (Gaspar &
Tapon, 2014; Matsui & Lai, 2013; Yu & Guan, 2013).
Ligands to GPCRs
Recently, a link between extracellular ligands and the Hippo
pathway has been identiﬁed (Miller et al., 2012; Yu et al.,
2012) (Fig. 2). Under serum deprivation condition, LATS1/2
are activated independent of MST1/2 and thereby phos-
phorylate and inactivate YAP/TAZ. Treatment with
lysophosphatidic acid (LPA) and sphingosine-1-phosphate
(S1P), two major lipids in serum, results in the dephospho-
rylation and accumulation of TAZ via the corresponding
GPCRs and the cognate Gα12/13 (Miller et al., 2012; Yu
et al., 2012). Consistent with the role of LPA and S1P in
modulating TAZ, Zhou et al. demonstrated that estrogen
could also induce the activation of TAZ in multiple breast
cancer cells. Stimulation of GPER, the G protein-coupled
estrogen receptor, activates Gαq/11, PLCβ-PKC, and Rho-
ROCK to inactivate LATS1/2, leading to the dephosphory-
lation and accumulation of TAZ. More importantly, total TAZ
level and nuclear TAZ correlate with GPER expression in
human invasive ductal breast cancer specimens (Zhou et al.,
2015a). Mo et al. also proved that thrombin, the ligand of
protease-activating receptors (PAR1) could induce dephos-
phorylation and activation of TAZ in a similar mechanism (Mo
et al., 2012). In contrast to Gα12/13, Gαq/11, and Gαi/o, Gαs
plays an opposing role on TAZ activation. Yu et al. found that
overexpression of Gαs induces LATS1/2 activation and TAZ
phosphorylation (Yu et al., 2012). The ligands, such as glu-
cagon and dobutamine which can stimulate Gαs, indeed
abolish the activation of TAZ (Bao et al., 2011; Yu et al.,
2012). Cyclic adenosine monophosphate (cAMP), a second
messenger downstream of Gαs-couple receptors, mediates
Gαs-induced TAZ inactivation via PKA and Rho GTPase (Yu
et al., 2013). GPCRs represent the largest family of mem-
brane receptors in mammals and mediate numerous signals
during physiological and pathological conditions. The link
between GPCRs and the Hippo signaling pathway provides
novel insights into the regulation of TAZ, implying the
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multiple functions of TAZ in different cell types and different
circumstances (Yu & Guan, 2013; Zhou et al., 2015b). G
proteins and GPCRs are frequently altered in human can-
cers (Kan et al., 2010; O’Hayre et al., 2013). Recently, two
groups found that around 80% of uveal melanoma harbor
GNAQ or GNA11 mutation and YAP/TAZ are constitutively
stimulated in these specimens (Feng et al., 2014; Yu et al.,
2014). Verteporﬁn (VP), an inhibitor of YAP/TAZ-TEADs
interaction, blocks the tumor growth of uveal melanomas
carrying mutations in GNAQ and GNA11. These studies add
the possibility of using YAP/TAZ as therapeutic targets for
cancer treatment. We look forward to seeing more follow-up
studies on GPCRs and the Hippo-YAP/TAZ pathway, which
would uncover the multiple regulations on this exciting
pathway and accelerate the discovery of new cancer treat-
ment approaches.
Metabolism and nutrient
Metabolism switch is one of the hallmarks of cancer
(Hanahan & Weinberg, 2011). Recent studies have impli-
cated that energy status, glycolysis and mevalonate
biosynthesis could modulate YAP/TAZ activities (Fig. 2).
These studies suggest that TAZ could response to and
coordinate with the nutrient status to regulate gene tran-
scription and cell proliferation.
Glucose metabolism is a central metabolism pathway to
produce energy and carbon for the building blocks of cellular
synthesis. Metabolic reprogramming from oxidative respira-
tion to aerobic glycolysis commonly happens in cancer cells,
which is called Warburg effect (Hanahan & Weinberg, 2011;
Warburg, 1956a; Warburg, 1956b). Growing evidence sug-
gests that the aerobic glycolysis can support the oncogenic
signaling to foster tumor malignancy. Recent studies con-
nected the energy status to the Hippo-YAP/TAZ pathway
(Mo et al., 2015; Wang et al., 2015b). Under glucose depri-
vation, LATS1/2 are strongly activated and thereby inhibit
TAZ (Mo et al., 2015). AMPK, one of the major kinases
sensing glucose, phosphorylates AMOTL1 and hence acti-
vates LATS1/2 (DeRan et al., 2014). A second proposed
model is that AMPK can phosphorylate YAP directly at serine
94 which is required for its interaction with TEADs (Mo et al.,
2015; Wang et al., 2015a). However, whether this mecha-
nism is conserved in the regulation of TAZ by energy status
remains unclear. Glucose could activate YAP/TAZ in a way
independent of AMPK and LATS1/2 (Enzo et al., 2015).
When glucose uptake or a shift from glycolysis to oxidative
phosphorylation is blocked, the transcriptional activities of

















































Figure 2. Regulation of the Hippo pathway by multiple upstream signals. Gαq/11-, Gα12/13-, and Gαi/o-coupled GPCRs signals
activate YAP/TAZ via promoting Rho GTPase activation and cytoskeleton assembling, leading to the inhibition of LATS1/2 kinase
activity; while Gαs-coupled GPCRs exert opposing roles on YAP/TAZ activation. The mevalonate cholesterol biosynthesis pathway,
which is required for membrane localization and activation of Rho GTPase, promotes YAP/TAZ nuclear localization and activation.
Inhibition of the mevalonate pathway is a potential way to target YAP/TAZ in human cancer. Under glucose deprivation condition,
AMPK is activated to inhibit YAP/TAZ via direct phosphorylation on YAP/TAZ or via AMOTL-LATS1/2 axis.
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formation between TEADs and YAP/TAZ (Enzo et al., 2015).
Mechanistically, they showed that PFK1 (phosphofructoki-
nase), the enzyme of the ﬁrst committed step of glycolysis,
interacts with TEADs, and the transcriptional coactivation
activity of TAZ is reduced when PFK1 is knocked-down.
(Enzo et al., 2015). Moreover, in a large dataset of primary
human mammary tumors, YAP/TAZ activities are increased
in high-grade (G3 vs. G1) tumors and strongly associated
with genes regulated by glucose metabolism and breast
cancer malignancy (Conley et al., 2012; Schwab et al.,
2012). All these ﬁndings suggest that the activity of TAZ is
tightly modulated by glucose uptake or glycolysis, and TAZ is
one of the key downstream effects mediating the transcrip-
tional reprogramming upon glucose status ﬂuctuation. Under
glucose crisis, TAZ is restricted to prevent further exhaustion
to maintain cell survive.
Coincidently, Sorrentino et al. screened a library con-
taining 650 FDA-approved compounds and found that sta-
tins which are inhibitors of HMGCR (HMG-CoA reductase)
could profoundly decrease YAP/TAZ nuclear localization
(Sorrentino et al., 2014). Mechanistically, HMGCR is the
rate-limiting enzyme of the mevalonate pathway which pro-
duces geranylgeranyl pyrophosphate (GGPP) for prenylation
and membrane association of Rho GTPase, and it has been
well-established that Rho GTPase can act as an activator of
TAZ (Dupont et al., 2011; Yu et al., 2012; Zhao et al., 2012).
Furthermore, inhibition of geranylgeranyl transferase,
another enzyme of the mevalonate pathway, by GGTI-2133
impressively reduced the activity of YAP (Wang et al., 2014).
Although Wang et al. didn’t test GGTI-2133’s effect on TAZ, it
should have a similar impact as on YAP. It makes sense that
perturbing Rho GTPase by these compounds is sufﬁcient to
modulate TAZ activity because Rho/ROCK/F-actin plays a
central role in regulating the Hippo-YAP/TAZ pathway.
Screening or modifying the compounds targeting the
mevalonate pathway would be one direction to inhibit the
oncogenic roles of TAZ in human cancer.
Hypoxia
Hypoxia is one of the crucial microenvironmental factors that
promote tumorigenesis (Vaupel & Mayer, 2007; Wilson &
Hay, 2011). Hypoxia has also been shown to induce the
tumor-initiating activity of cancer stem cells in breast cancer
through regulating the activity of hypoxia-inducible factors
(HIFs) (Conley et al., 2012; Schwab et al., 2012). Recent
studies imply that there is a bidirectional crosstalk between
HIF-1 and TAZ to co-regulate gene transcription under
hypoxia environment. Xiang et al. reported that the TAZ is
regulated by hypoxia condition to induce breast cancer stem
cell phenotype in two discrete mechanisms (Xiang et al.,
2014). First, the mRNA level of TAZ and its target genes are
upregulated under hypoxia condition (1% O2) in multiple
breast cancer cell lines, and this phenomenon is dependent
on HIF-1. They further conﬁrmed that HIF-1 binds directly to
the HRE (HIF response element) which locates between
exon 2 and exon 3 ofWWTR1 gene under hypoxia condition,
and promotes the transcription of TAZ; second, the authors
found that there is more nuclear TAZ under hypoxia condi-
tion. Mechanistically, they observed that the proteasome
degradation of LATS2, which is the upstream kinase of TAZ
in the Hippo signaling pathway, is induced by hypoxia in an
HIF-1 and SIAH1 dependent manner (Xiang et al., 2014).
Moreover, based on the analysis of human breast cancer
database, the author found that only simultaneous TAZhigh
and HIF-1high expression status is correlated with worse
survival. Consistently, Yan et al. found that both the hypoxia
condition (1% O2) and hypoxia mimics (DMOG and CoCl2)
promote TAZ expression via an HIF-1α-dependent manner
in ovarian cancer cells (Yan et al., 2014). Interestingly, the
follow-up study from Xiang and colleagues demonstrate that
TAZ and HIF-1α interact with each other and functionally
serve as reciprocal transcriptional co-factors. HIF-1α serves
as a coactivator of TAZ/TEADs complex for the transcription
of target genes (such as CTGF) and TAZ serves as a
coactivator of HIF-1α for the transcription of target genes
(such as PDK1 and LDHA) in hypoxic human breast cancer
cells. Either knockdown of TAZ or HIF-1α decreases the
enrichment of HIF1 or TAZ in HRE of PDK1 (Xiang et al.,
2015). One consistent observation was found by Bendinelli
and colleagues (Bendinelli et al., 2013). They showed that
HIF-1α and TAZ interact with each other and are co-localized
in the nucleus after hypoxia. More importantly, the activity of
HIF-1 is tightly regulated by TAZ, indicating that TAZ may be
involved in the bone metastasis of breast cancer under
hypoxic microenvironment (Bendinelli et al., 2013). The
crosstalk between HIF-1 and TAZ increases the transcrip-
tional activity of both pathways and contributes to the gene
expression under hypoxic microenvironment. Therapeutic
strategies that inhibit HIF-1α or TAZ or combination of both
may improve the cancer treatment, especially for solid
tumors that suffer from severe hypoxic condition inside the
tumors.
Osmotic stress
TAZ is highly expressed in kidney, and TAZ knockout mice
develop multiple renal cysts and urinary concentration
defects (Hossain et al., 2007; Makita et al., 2008). However,
the molecular mechanism of how TAZ functions in renal cells
remains elusive. A recent study showed that hyperosmotic
stress selectively enhanced the phosphorylation of TAZ at
tyrosine 316 via c-Abl activation, and this site-speciﬁc
phosphorylation is required for TAZ interaction with NFAT5 in
response to osmotic stress. Moreover, the phosphorylated
TAZ suppressed the DNA-binding and transcriptional activity
of NFAT5 (Jang et al., 2012). This ﬁnding raised an intriguing
hypothesis that TAZ may work as a transcriptional co-re-
pressor in renal cells under hypertonic conditions, and the
physiological signiﬁcance of this phenomenon remains to be
explored. As we know, serine 89 is the major phosphorylated
site in TAZ by LATS1/2, and phosphorylation at this site
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leads to the cytoplasm retardation and inactivation of TAZ
(Huang et al., 2012; Lei et al., 2008; Liu et al., 2010).
Therefore, it’s interesting to test whether the phosphorylation
status of serine 89 in TAZ is altered upon osmotic stress. In
contrast, Jung-Soon Mo et al. showed that osmotic stress
cannot induce TAZ phosphorylation using a phos-tag gel in
HEK293A cells (Mo et al., 2015). It should be noticed that
these two groups use different cell lines and different
methods to induce osmotic stress, and these may be the
reasons for the controversial results.
TAZ AND HUMAN CANCERS
In addition to the work done in cell culture, increasing num-
bers of studies have shown that TAZ are elevated or acti-
vated in multiple human cancers, including breast cancer,
glioblastoma, lung cancer, colorectal cancer, and oral
squamous cell carcinoma (See discussion below).
Breast cancer
TAZ protein level and activity are up-regulated in high-grade
metastatic breast cancers, and overexpression of TAZ is
sufﬁcient to induce breast cancer cell proliferation, transfor-
mation, and EMT (Chan et al., 2008; Cordenonsi et al., 2011;
Lei et al., 2008). Furthermore, TAZ is required for and sufﬁ-
cient to maintain self-renewal and tumor initiation capability
of breast cancer stem cells (Cordenonsi et al., 2011). Bar-
tucci and colleagues provide evidence that TAZ is required
for metastatic activity and chemoresistance of breast cancer
stem cells, and TAZ expression level negatively correlates
with shorter disease-free survival of breast cancer patients
(Bartucci et al., 2015). TAZ also serves as a biomarker for
decreased pathological complete response rate in luminal
B/HER2-positive breast cancer patients who received
neoadjuvant trastuzumab or chemotherapy (Vici et al.,
2014). TAZ expression level is signiﬁcantly correlated with
GPER, G protein-coupled receptor of estrogen, in human
invasive ductal breast cancer, and may contribute to
tamoxifen resistance of breast cancer therapy (Zhou et al.,
2015a). Extensive studies should focus on the mechanism of
the oncogenic role of TAZ in breast cancer development
using mouse model.
GBM (Glioblastoma multiforme)
Compared with the proneural (PN) GBMs and low-grade
gliomas, mesenchymal (MES) GBMs have elevated TAZ
expression due to the lower methylation level in its pro-
moter region (Bhat et al., 2011). Actually, TAZ could be
recruited to numerous mesenchymal gene promoters and
drives the mesenchymal feature of malignant glioma (Bhat
et al., 2011). Resistance to Temozolomide, one commonly
used chemotherapy drug for GBM, is frequently happened
(Hegi et al., 2005). Tian et al., showed that TAZ promotes
temozolomide resistance by reducing temozolomide-in-
duced apoptosis. High level of TAZ expression predicts a
poor outcome of GBM patients (Tian et al., 2015). Glioma
cancer stem cells (GSCs) are one of the major reasons for
chemotherapy resistance in GBM patients (Bao et al.,
2006). Since we have already known that TAZ is required
for and sufﬁcient to maintain self-renewal and tumor initia-
tion capability of breast cancer stem cells (Cordenonsi
et al., 2011), it’s interesting to study whether TAZ-induced
temozolomide resistance is related to TAZ’s function in
GSCs.
Lung adenocarcinoma
TAZ was ﬁrstly identiﬁed as an oncogene in non-small cell
lung cancer (NSCLC) in 2011 (Zhou et al., 2011). TAZ
expression is a prognostic indicator for worse survival in
resected NSCLC (Noguchi et al., 2014; Xie et al., 2012).
Knockdown of TAZ in NSCLC cell lines is sufﬁcient to sup-
press proliferation, invasion, and tumor growth (Wang et al.,
2010; Zhou et al., 2011). Additionally, a YAP/TAZ gene
expression signature is signiﬁcantly associated with tumor-
propagating cells and human lung cancer progression (Lau
et al., 2014). A higher level of TAZ indicates worse overall
survival and more frequent metastasis in lung adenocarci-
noma patients (Lau et al., 2014). The highly expressed TAZ
in NSCLC may also be on the reasons for geﬁtinib resistance
in cells harboring EGFR-T790M mutation (Xu et al., 2015).
It’s worthy to study TAZ’s function in lung cancer systemi-
cally because TAZ knockout mice develop multiple renal
cysts and lung emphysema (Hossain et al., 2007; Makita
et al., 2008).
Colorectal cancer
Recent two studies provided evidence that TAZ expression
is an independent prognostic indicator in colorectal cancer
(Wang et al., 2013; Yuen et al., 2013). Colorectal cancer
patients carrying co-overexpression of YAP and TAZ have a
worse outcome than those who have either one alone (Wang
et al., 2013). Knockdown of YAP and TAZ in colorectal
cancer cells reduces the proliferation, metastasis, and
invasion (Wang et al., 2013).
Oral squamous cell carcinoma
Several studies observed that the expression of TAZ in
tongue squamous cell carcinoma signiﬁcantly correlated with
tumor size, pathological grade, and clinical stage. Higher
expression of TAZ is negatively associated with overall
survival and disease-free survival (Hiemer et al., 2015; Li
et al., 2015b; Wei et al., 2013). Notably, TAZ is also required
for the maintenance of self-renewal and tumor initiation
ability of oral cancer stem cells (Li et al., 2015b).
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A recent study demonstrated that KS-associated her-
pesvirus (KSHV), a GPCR, activates Gαq/11 and Gα12/13 to
inhibit LATS1/2 and thereby dephosphorylates and activates
TAZ (Liu et al., 2015). They also showed that the expression
level of TAZ is elevated in human Kaposi sarcoma speci-
mens (Liu et al., 2015).
Epithelioid hemangioendothelioma
Based on the documents and TCGA database, rare muta-
tions of TAZ were observed in human cancer specimens
(Harvey et al., 2013; Yu et al., 2015). Recently, chromosomal
translocation of TAZ was found in a rare vascular sarcoma
termed epithelioid hemangioendothelioma. Remarkably,
gene fusion of WWTR1-CAMTA1 (calmodulin-binding tran-
scription activator 1) happens in virtually all epithelioid
hemangioendothelioma (Errani et al., 2011; Tanas et al.,
2011). Mechanistically, TAZ-CAMTA1 fusion results in
nuclear localization and constitutive activation of TAZ (Tanas
et al., 2016).
As we discussed above, overexpression or hyperactiva-
tion of TAZ is widespread in human cancers, indicating that
TAZ is important for the development and sustainability of
neoplasia. Actually, in vitro cell culture studies showed that
either gain or loss of TAZ can enhance or suppress
cancerous phenotypes in a wide range of cell lines. Con-
sistent with the observation that TAZ is highly expressed in
multiple human cancers, TAZ displays the transforming
properties in cell culture system. Over-expression of TAZ in
cultured cells leads to cancer features such as anchorage-
independent growth (Chan et al., 2011; Yang et al., 2012),
epithelial to mesenchymal transition (EMT) (Chan et al.,
2008; Cordenonsi et al., 2011; Hong et al., 2005; Lei et al.,
2008), growth-factor-independent proliferation (Yang et al.,
2012), resistance to chemotherapeutics (Xu et al., 2015),
increased migration, invasion, tumor-initiation properties,
and tumor formation in xenograft models (Bartucci et al.,
2015; Cordenonsi et al., 2011; Lau et al., 2014; Yuen et al.,
2013). In addition, TAZ endows self-renewal capability of
breast cancer cells to sustain the cancer stem cells popu-
lation (Cordenonsi et al., 2011). Concordantly, loss of TAZ
inhibits cancerous phenotypes in cancer cell lines (Bartucci
et al., 2015; Cordenonsi et al., 2011; Lau et al., 2014; Yuen
et al., 2013; Zanconato et al., 2015). For example, the
capability of anchorage-independent growth, migration,
invasion, and tumorigenesis of MCF7 breast cancer cells is
decreased when TAZ is knocked-down (Chan et al., 2008).
Likewise, siRNA knockdown of TAZ in A549 cells inhibits
anchorage-independent growth and tumor growth in mice
(Zhou et al., 2011). Collectively, TAZ plays an important role
in tumorigenesis via regulating multiple aspects of cancer
cells, implying that TAZ could be served as a nice candidate
for cancer diagnosis or therapy.
TARGETING TAZ FOR CANCER THERAPY
Accumulating studies provide evidence that TAZ is an
oncoprotein during tumorigenesis, leading us to consider the
therapeutic beneﬁts of TAZ inhibition in cancer (Bhat et al.,
2011; Chan et al., 2008; Zhang et al., 2009). Kinases always
serve as the best targets for small-molecular inhibitors.
However, unlike most oncogenic kinases in cancer, the
kinases in the Hippo pathway are tumor suppressors. This
means it is unlikely to kill the cancer cells if we target the
kinases in the Hippo pathway by small-molecular inhibitors.
Other ways should be explored beyond targeting the core
kinases module.
The major readout of the Hippo-YAP/TAZ pathway is
modulating the downstream target gene transcription via
interacting with and coactivating TEADs transcription factors
(Zhang et al., 2009). Compounds which disrupt the interac-
tion between TAZ-TEADs are considered as good candi-
dates for inhibition of the oncogenic roles of TAZ (Sudol
et al., 2012). Liu-Chittenden et al. screened around 3000
compounds and found that members of the porphyrin family,
such as verteporﬁn (VP), hematoporphyrin (HP), and proto-
porphyrin IX (PPIX), are strong candidates of YAP/TAZ
inhibitors (Liu-Chittenden et al., 2012). Verteporﬁn, which is a
clinical photosensitizer in photocoagulation therapy for
macular degeneration, strikingly dissociates the interaction
between YAP/TAZ and TEADs and thereby inhibits the
downstream target genes transcription. More importantly,
verteporﬁn blocked YAP-induced liver tumorigenesis and
also exhibits an anti-cancer effect on uveal melanoma cells
carrying GNAQ mutations (Liu-Chittenden et al., 2012).
However, we couldn’t exclude the possibility that verteporﬁn
can inhibit cancer cell proliferation and induce cancer cell
death in a way independent of YAP/TAZ (Zhang et al.,
2015a). Recent studies showed that VGLL4 is a novel
negative regulator of YAP-TEADs complex, and a peptide
mimicking VGLL4 suppressed tumor growth of human pri-
mary gastric cancer in nude mice (Jiao et al., 2014; Zhang
et al., 2014). Based on the structure of the YAP/TEAD
complex, VGLL4 should display a similar effect on disrupting
the interaction between TAZ and TEADs.
Another possibility of abolishing TAZ activity is disturbing
the upstream regulators. As we discussed above, Rho
GTPase and actin cytoskeleton exhibit central role in the
regulation of the Hippo-YAP/TAZ in response to a wide range
of upstream signals (Yu et al., 2015). Hence, inhibition of
Rho GTPase would activate LAT1/2 kinase activity and
thereby inhibit TAZ. Recently, Sorrentino et al. found that
statins, inhibitors of HMGCR which is the rate-limiting
enzyme of the mevalonate pathway, could strongly reduce
YAP/TAZ nuclear localization (Sorrentino et al., 2014). The
mevalonate pathway is essential for prenylation, membrane
association, and activation of Rho GTPase. Inhibition of
HMGCR strongly activates LATS1/2 and reduces the tran-
scriptional activity of TAZ, hence exhibiting anti-proliferation
and apoptotic effects on breast cancer (Sorrentino et al.,
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2014). It’s intriguing to test whether other clinically used
inhibitors of the mevalonate pathway, such as zoledronic
acid (FDPS inhibitor), GGTI-2133 (GGPP inhibitor), and
fatostatin (SREBP inhibitor), have a similar effect as statins.
The above studies clearly indicate a powerful therapeutic
capacity of targeting TAZ in human cancer. Further investi-
gation of the regulation and function of TAZ will help us to
uncover the mystery of this amazing protein and apply these
ﬁnding to cancer therapy.
OUTSTANDING QUESTIONS
Since TAZ was ﬁrstly identiﬁed as a 14-3-3 binding protein in
2000, rapid research progress has been achieved for a better
understanding of TAZ. However, some key questions remain
unanswered, and new questions arise. Here we listed below
some of the key questions that should be addressed.
(1) What’s the difference between TAZ and YAP? TAZ
and YAP contain similar domains/motifs, including 14-3-3
binding motif, WW domain, coiled-coil domain, and a PDZ-
binding motif. As downstream effectors of the Hippo signal-
ing pathway, YAP and TAZ are also similarly regulated.
However, these two proteins have distinct tissue expression
pattern (Kanai et al., 2000; Sudol et al., 1995), indicating
different functions in speciﬁc organs.
(2) Are there any other regulatory posttranslational mod-
iﬁcations happening on TAZ beside phosphorylation and
polyubiquitylation? TAZ can be phosphorylated by LATS1/2,
GSK3, CK1, c-Abl, and Cdk1, and these phosphorylated
sites are involved in the regulation of subcellular localization,
stability, and activity of TAZ. Other modiﬁcations on TAZ may
provide novel insight into the regulation and function of TAZ.
(3) How does cytoskeleton dynamic regulate LATS1/2
activity? Increasing evidence points out that cytoskeleton
remodeling plays a central role in the regulation of the Hippo
pathway in response to multiple intrinsic and extracellular
signals. However, the kinase which senses the signal from
cytoskeleton remodeling and then phosphorylates LATS1/2
remains elusive.
(4) How could we utilize TAZ as a therapeutic target in
human cancer? To answer this question, we should study
the regulation and function of TAZ extensively in cancer
cells, especially using the mouse cancer model. Accumu-
lating studies suggest that TAZ could be regulated by a
broad range of signals, leading us to reconsider the way we
could use to modulate the activity of TAZ in cancers with high
expression level of TAZ.
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